$10.00
0.60%
Nasdaq, Nov 28, 07:37 pm CET
ISIN
US76029N1063
Symbol
REPL

Replimune Group, Inc. Stock price

$10.00
-0.45 4.31% 1M
+1.57 18.62% 6M
-2.11 17.42% YTD
-4.05 28.83% 1Y
-9.40 48.45% 3Y
-41.68 80.65% 5Y
-5.16 34.04% 10Y
-5.16 34.04% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.06 0.60%
ISIN
US76029N1063
Symbol
REPL
Industry

Key metrics

Basic
Market capitalization
$784.4m
Enterprise Value
$533.2m
Net debt
positive
Cash
$323.6m
Shares outstanding
78.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
75.4%
Return on Equity
-59.5%
ROCE
-95.1%
ROIC
-558.6%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-317.6m | $-352.9m
EBIT
$-320.0m | $-307.3m
Net Income
$-309.9m | $-244.0m
Free Cash Flow
$-269.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-38.8% | -36.2%
EBIT
-38.4% | -17.4%
Net Income
-45.4% | 1.3%
Free Cash Flow
-43.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.4
FCF per Share
$-3.4
Short interest
39.8%
Employees
331
Rev per Employee
$0.0
Show more

Is Replimune Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Replimune Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Replimune Group, Inc. forecast:

11x Buy
73%
3x Hold
20%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Replimune Group, Inc. forecast:

Buy
73%
Hold
20%
Sell
7%

Financial data from Replimune Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 102 102
74% 74%
-
- Research and Development Expense 215 215
27% 27%
-
-318 -318
39% 39%
-
- Depreciation and Amortization 2.43 2.43
0% 0%
-
EBIT (Operating Income) EBIT -320 -320
38% 38%
-
Net Profit -310 -310
45% 45%
-

In millions USD.

Don't miss a Thing! We will send you all news about Replimune Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Replimune Group, Inc. Stock News

Neutral
GlobeNewsWire
22 days ago
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure
Neutral
GlobeNewsWire
24 days ago
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2025 and provided a business update.
Positive
The Motley Fool
about one month ago
Biotech stocks can be volatile, a tendency that was very much in Replimune Group's (REPL 100.00%) favor on Monday. The biotech's stock had more than doubled in late-session action, thanks to some very positive news on the regulatory front.
More Replimune Group, Inc. News

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Head office United States
CEO Sushil Patel
Employees 331
Founded 2015
Website www.replimune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today